Skip to main content

Table 2 Estimated probability of dual therapy discontinuation by cause (Kaplan-Meier survival analysis)

From: Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter observational study

 

1 year

3 years

5 years

Overall

13.3 %

26.5 %

36.2 %

Virological failure

5.4 %

14.2 %

21.7 %

Toxicity

7.5 %

13.5 %

13.5 %

Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us